Personal information

Websites & social links

Cambridge Stem Cell Institute

Other IDs

ResearcherID: E-6725-2014

Activities

Collapse all

Employment (14)

University of Cambridge: Cambridge, GB

2020-10-01 to present | Head of Department (Department of Haematology)
Employment
Source: Self-asserted source
Huntly, BJP

University of Cambridge: Cambridge, Cambridgeshire, GB

2016-10-01 to present | Professor of Leukaemia Stem Cell Biology (Department of Haematology & Stem Cell Institute)
Employment
Source: Self-asserted source
Huntly, BJP

Cambridge University Hospitals: Cambridge, GB

2003-01-01 to present | Honorary Consultant (Haematology)
Employment
Source: Self-asserted source
Huntly, BJP

University of Cambridge: Cambridge, Cambridgeshire, GB

2013-10-01 to 2016-09-30 | Reader in Leukaemia Stem Cell Biology (Department of Haematology & Stem Cell Institute)
Employment
Source: Self-asserted source
Huntly, BJP

University of Cambridge: Cambridge, Cambridgeshire, GB

2009-01-01 to 2013-09-30 | University Senior Lecturer (Department of Haematology)
Employment
Source: Self-asserted source
Huntly, BJP

University of Cambridge: Cambridge, Cambridgeshire, GB

2005-10-01 to 2008-12-31 | MRC Senior Clinical Fellow (Cambridge Institute for Medical Research)
Employment
Source: Self-asserted source
Huntly, BJP

Brigham and Women's Hospital: Boston, MA, US

2003-01-01 to 2005-09-30 | Leukaemia Research Fund Senior Fellow (Division of Hematology)
Employment
Source: Self-asserted source
Huntly, BJP

Cambridge University Hospitals: Cambridge, GB

2001-08-01 to 2002-12-31 | Specialist Registrar (Haematology)
Employment
Source: Self-asserted source
Huntly, BJP

University of Cambridge: Cambridge, Cambridgeshire, GB

1998-08-01 to 2001-07-31 | MRC Clinical Training Fellow (Department of Haematology)
Employment
Source: Self-asserted source
Huntly, BJP

Ninewells Hospital: Dundee, Dundee, GB

1994-08-01 to 1998-07-31 | Specialist Registrar (Haematology)
Employment
Source: Self-asserted source
Huntly, BJP

Eastern General Hospital: Edinburgh, GB

1993-08-01 to 1994-07-31 | Registrar in Medicine
Employment
Source: Self-asserted source
Huntly, BJP

Edinburgh and Lothian Hospitals: Edinburgh, GB

1991-08-01 to 1993-07-31 | Senior House Officer
Employment
Source: Self-asserted source
Huntly, BJP

Northern and Western General Hospitals: Edinburgh, GB

1991-02-01 to 1991-07-31 | House Officer
Employment
Source: Self-asserted source
Huntly, BJP

Victoria Hospital: Kirkcaldy, Fife, GB

1990-08-01 to 1991-01-31 | House Officer (Surgery)
Employment
Source: Self-asserted source
Huntly, BJP

Education and qualifications (5)

Specialist Training Authority: London, GB

CCST
Qualification
Source: Self-asserted source
Huntly, BJP

Royal College of Physicians: London, London, GB

MRCP
Qualification
Source: Self-asserted source
Huntly, BJP

Royal College of Pathologists: London, London, GB

FRCPath
Qualification
Source: Self-asserted source
Huntly, BJP

University of Cambridge: Cambridge, Cambridgeshire, GB

1998-10-01 to 2003-01-21 | PhD (Department of Haematology)
Qualification
Source: Self-asserted source
Huntly, BJP

University of Edinburgh: Edinburgh, Edinburgh, GB

1985-09-01 to 1990-07-31 | MB ChB (Medicine)
Qualification
Source: Self-asserted source
Huntly, BJP

Professional activities (9)

International Society for Experimental Hematology: Chicago, Illinois, US

Service
Source: Self-asserted source
Huntly, BJP

European Hematology Association: Den Haag, Zuid-Holland, NL

Membership
Source: Self-asserted source
Huntly, BJP

Cambridge Stem Cell Institute: Cambridge, Cambridgeshire, GB

2016-08-01 to present | Lead (Malignat Stem Cells)
Invited position
Source: Self-asserted source
Huntly, BJP

Wellcome Sanger Institute: Cambridge, GB

2012-12-01 to present | Visiting Scientist
Invited position
Source: Self-asserted source
Huntly, BJP

Academy of Medical Sciences: London, GB

2021-05-12 | Fellowship
Distinction
Source: Self-asserted source
Huntly, BJP

European Hematology Association: The Hague, NL

2020-10-01 | Board Member
Distinction
Source: Self-asserted source
Huntly, BJP

University of Cambridge: Cambridge, Cambridgeshire, GB

2016-06-01 | Director (Clinical Academic Training Office)
Distinction
Source: Self-asserted source
Huntly, BJP

CRUK Cambridge Programme: Cambridge, GB

2016-03-01 | Co-Lead (Training)
Distinction
Source: Self-asserted source
Huntly, BJP

CRUK Cambridge Centre : Cambridge, GB

2016-03-01 | Co-Lead (Haematological Malignancies Programme)
Distinction
Source: Self-asserted source
Huntly, BJP

Funding (18)

Elucidating non-genetic mechanisms of resistance to the combined BCL2/BCL-XL inhibitor AZD0466 in AML to inform future rational combinations

2021-06 to 2023-06 | Grant
AstraZeneca (Cambridge, GB)
Source: Self-asserted source
Huntly, BJP

Gene regulatory networks in normal and malignant hematopoiesis – identification and targeting

2020-12 to 2023-11 | Grant
“la Caixa” Foundation (Madrid, ES)
Source: Self-asserted source
Huntly, BJP

Harmony: Healthcare alliance for resourceful medicines offensive against neoplasms in hematology - Plus

2020-10 to 2023-09 | Grant
Innovative Medicines Initiative (Brussels, BE)
Source: Self-asserted source
Huntly, BJP

Organic opto-acoustic electronics for early stage detection of cancer

2020-04 to 2022-03 | Grant
Cancer Research UK (London, GB)
Source: Self-asserted source
Huntly, BJP

Cross talk between repressive histone modifications and DNA methylation in the pathogenesis and evolution of myeloid malignancies

2019-03 to 2022-02 | Grant
Kay Kendall Leukaemia Fund (London, GB)
Source: Self-asserted source
Huntly, BJP

Enhancer subversion and its role in the generation and maintenance of Acute Myeloid Leukaemia

2019-02 to 2024-01 | Grant
Cancer Research UK (London, GB)
GRANT_NUMBER:

C18680/A25508
Source: Self-asserted source
Huntly, BJP

Elucidation of cellular and molecular mechanisms of lymphoma induction and evolution to identify therapeutic targets

2018-02-01 to 2021-01-31 | Grant
Medical Research Council (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.7747838
GRANT_NUMBER: MR/R009708/1
Source: Self-asserted source
Huntly, BJP via DimensionsWizard

Deciphering the role of epigenetic regulators in the evolution of pre-leukeamic to leukaemia using mouse models of AML

2018-01-01 to 2020-07-01 | Grant
Blood Cancer UK (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.7751212
GRANT_NUMBER:

BW-17006
Source: Self-asserted source
Huntly, BJP via DimensionsWizard

Harmony: Healthcare alliance for resourceful medicines offensive against neoplasms in hematology

2017-01 to 2021-12 | Grant
Innovative Medicines Initiative (Brussels, BE)
Source: Self-asserted source
Huntly, BJP

COMAL:COhesin Mutations in Acute Leukemia: from modeling and mechanisms to novel therapeutics

2015-09-01 to 2020-08-31 | Grant
European Research Council (Brussels, BE)
URL: https://app.dimensions.ai/details/grant/grant.4273512
GRANT_NUMBER: 647685
Source: Self-asserted source
Huntly, BJP via DimensionsWizard

Characterising and targeting aberrant enhancer function in acute myeloid leukaemia (AML)

2015-03-29 to 2018-03-28 | Grant
Medical Research Council (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.4107097
GRANT_NUMBER: MR/M010392/1
Source: Self-asserted source
Huntly, BJP via DimensionsWizard

The role of XRCC5 and SAFB1 in the transforming activity of HOXA9 in acute myeloid leukaemia

2014-06-01 to 2017-05-31 | Grant
Worldwide Cancer Research (St Andrews, GB)
URL: https://app.dimensions.ai/details/grant/grant.5146155
GRANT_NUMBER:

WCR-14-1069
Source: Self-asserted source
Huntly, BJP via DimensionsWizard

Kay Kendall Leukaemia Fund

2014-01 to 2018-05 | Grant
Kay Kendall Leukaemia Fund (London, GB)
GRANT_NUMBER:

Reconciling the role of the epigenetic regulator CBP in tumour suppression and haematopoietic stem and progenitor function
Source: Self-asserted source
Huntly, BJP

Generation and characterisation of genetically modified murine models for the study of Acute Myeloid Leukaemia with a normal karyotype

2012-12-03 to 2018-01-02 | Grant
Blood Cancer UK (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.9693917
GRANT_NUMBER:

11044
Source: Self-asserted source
Huntly, BJP via DimensionsWizard

Role of BET proteins in transformation and transcriptional dysregulation by mutant Nucleophosmin in AML

2012-11-01 to 2015-10-31 | Grant
Bloodwise (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.7551248
GRANT_NUMBER:

12034
Source: Self-asserted source
Huntly, BJP via DimensionsWizard

Integrated genomic, proteomic and functional analysis of the mechanisms of transcriptional dysregulation by the NUP98-HOXA9 fusion in AML

2010-10-01 to 2014-06-30 | Grant
Bloodwise (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.7551098
GRANT_NUMBER:

10010
Source: Self-asserted source
Huntly, BJP via DimensionsWizard

Self-renewal in Leukaemia Stem Cells: identification of novel self-renewal pathways and the role of homeobox proteins

2005-10-09 to 2010-10-08 | Grant
Medical Research Council (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.2783876
GRANT_NUMBER: G116/187
Source: Self-asserted source
Huntly, BJP via DimensionsWizard

Mechanisms of transformations by tyrosine kinase fusion proteins and their cooperativity in acute leukaemia

2003-01-01 to 2005-12-31 | Grant
Bloodwise (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.7550451
GRANT_NUMBER:

0217
Source: Self-asserted source
Huntly, BJP via DimensionsWizard

Works (50 of 120)

Items per page:
Page 1 of 3

Differential inflammatory conditioning of the bone marrow by acute myeloid leukemia and its impact on progression

Blood Advances
2024-10-08 | Journal article
DOI: 10.1182/bloodadvances.2024012867
Contributors: Valentina R. Minciacchi; Christina Karantanou; Jimena Bravo; Raquel S. Pereira; Costanza Zanetti; Theresa Krack; Rahul Kumar; Katrin Bankov; Sylvia Hartmann; Brian J. P. Huntly et al.
Source: check_circle
Crossref

The long-range gene regulatory landscape of cerebellar granule neuron progenitors

2024-08-22 | Preprint
DOI: 10.1101/2024.08.22.609103
Contributors: Kimberley L. H. Riegman; Charlotte George; Danielle E. Whittaker; Mohi U. Ahmed; Haiyang Yun; Brian J. P. Huntly; David Sims; Cameron S. Osborne; M. Albert Basson
Source: check_circle
Crossref

A guide to epigenetics in leukaemia stem cells

Molecular Oncology
2023-12 | Journal article
DOI: 10.1002/1878-0261.13544
Contributors: Shuchi Agrawal‐Singh; Jaana Bagri; Nathalie Sakakini; Brian J. P. Huntly
Source: check_circle
Crossref

MAT2A inhibition in AML unveils therapeutic potential of combining DNA demethylating agents with UPR targeting

2023-06-07 | Preprint
DOI: 10.1101/2023.06.05.543499
Contributors: Keti Zeka; Alice V. Taylor; Ralph Samarista; Denise Ragusa; Chun-Wai Suen; Oliwia W. Cyran; Ana Filipa Domingues; Eshwar Meduri; Brian JP Huntly; Dorian Forte et al.
Source: check_circle
Crossref

A phase I/II open-label study of molibresib for the treatment of relapsed/refractory hematologic malignancies

Clinical Cancer Research
2022-11-09 | Journal article
DOI: 10.1158/1078-0432.CCR-22-1284
Contributors: Mark A. Dawson; Gautam Borthakur; Brian Huntly; Anastasios Karadimitris; Adrian Alegre; Aristeidis Chaidos; Dan T. Vogl; Daniel A. Pollyea; Faith E. Davies; Gareth J. Morgan et al.
Source: check_circle
Crossref

Targeting AML at the intersection of epigenetics and signaling

Science Signaling
2022-04-19 | Journal article
DOI: 10.1126/scisignal.abo0059
Contributors: Nisha Narayan; Brian J. P. Huntly
Source: check_circle
Crossref

Targeting Chromatin Regulation in Acute Myeloid Leukemia.

HemaSphere
2021-06-01 | Journal article
DOI: 10.1097/hs9.0000000000000589
PMID: 34095772
PMC: PMC8171376
Source: Self-asserted source
Huntly, BJP

Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses

Journal of Clinical Oncology
2021-03-10 | Journal article
DOI: 10.1200/JCO.20.01170
Contributors: Alan K. Burnett; Nigel H. Russell; Robert K. Hills; Stephen Knapper; Sylvie Freeman; Brian Huntly; Richard E. Clark; Ian F. Thomas; Lars Kjeldsen; Mary Frances McMullin et al.
Source: check_circle
Crossref

BETs Need Greens: Folate Deficiency and Resistance to MYC-Targeted Therapies

Cancer Discovery
2020-12-01 | Journal article
DOI: 10.1158/2159-8290.CD-20-1333
Contributors: Ludovica Marando; Brian J.P. Huntly
Source: check_circle
Crossref

Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy.

Cell metabolism
2020-09-22 | Journal article
DOI: 10.1016/j.cmet.2020.09.001
PMID: 32966766
PMC: PMC7658808
Source: Self-asserted source
Huntly, BJP

KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements.

Leukemia
2020-08-06 | Journal article
DOI: 10.1038/s41375-020-1001-z
PMID: 32764680
PMC: PMC7610570
Source: Self-asserted source
Huntly, BJP

CML: new tools to answer old questions

Blood
2020-06-25 | Journal article
DOI: 10.1182/blood.2020005599
Contributors: George Giotopoulos; Brian J. P. Huntly
Source: check_circle
Crossref

Dissecting the early steps of MLL induced leukaemogenic transformation using a mouse model of AML.

Nature communications
2020-03-16 | Journal article
DOI: 10.1038/s41467-020-15220-0
PMID: 32179751
PMC: PMC7075888
Source: Self-asserted source
Huntly, BJP

Loss of Kat2a enhances transcriptional noise and depletes acute myeloid leukemia stem-like cells.

eLife
2020-01-27 | Journal article
DOI: 10.7554/elife.51754
PMID: 31985402
PMC: PMC7039681
Source: Self-asserted source
Huntly, BJP

Cohesin-dependent regulation of gene expression during differentiation is lost in cohesin-mutated myeloid malignancies.

Blood
2019-12-01 | Journal article
DOI: 10.1182/blood.2019001553
PMID: 31515253
PMC: PMC7484777
Source: Self-asserted source
Huntly, BJP

Genetic modification of primary human B cells to model high-grade lymphoma.

Nature communications
2019-10-04 | Journal article
DOI: 10.1038/s41467-019-12494-x
PMID: 31586074
PMC: PMC6778131
Source: Self-asserted source
Huntly, BJP

Kinase Networks Regulate Metabolism: I'D(H1) Never Have Guessed!

Cancer Discovery
2019-06-01 | Journal article
DOI: 10.1158/2159-8290.CD-19-0373
Contributors: Sarah Horton; Brian J.P. Huntly
Source: check_circle
Crossref

Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML.

The Journal of experimental medicine
2019-03-19 | Journal article
DOI: 10.1084/jem.20181276
PMID: 30890554
PMC: PMC6446874
Source: Self-asserted source
Huntly, BJP

SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4.

Nature communications
2018-12 | Journal article
DOI: 10.1038/s41467-018-07620-0
PMID: 30568163
PMC: PMC6300607
Contributors: Tzelepis K; De Braekeleer E; Aspris D; Barbieri I; Vijayabaskar MS; Liu WH; Gozdecka M; Metzakopian E; Toop HD; Dudek M et al.
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

Prognostic models turn the Heat(IT)up on FLT3ITD-mutated AML.

Clinical cancer research : an official journal of the American Association for Cancer Research
2018-11 | Journal article
DOI: 10.1158/1078-0432.ccr-18-3146
PMID: 30389660
Contributors: Gallipoli P; Huntly BJ
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

Intratumoral Heterogeneity: Tools to Understand and Exploit Clone Wars in AML.

Cancer cell
2018-10 | Journal article
DOI: 10.1016/j.ccell.2018.09.004
PMID: 30300577
Contributors: Giotopoulos G; Huntly BJP
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

Loss Of Kat2a Enhances Transcriptional Noise And Depletes Acute Myeloid Leukemia Stem-Like Cells

2018-10 | Other
DOI: 10.1101/446096
OTHER-ID:

PPR59286
Contributors: Domingues AF; Kulkarni R; Giotopoulos G; Gupta S; Tan S; Foerner E; Romano Adao R; Zeka K; Huntly BJ; Prabakaran S et al.
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

Population dynamics of normal human blood inferred from somatic mutations.

Nature
2018-09 | Journal article
DOI: 10.1038/s41586-018-0497-0
PMID: 30185910
Contributors: Lee-Six H; Øbro NF; Shepherd MS; Grossmann S; Dawson K; Belmonte M; Osborne RJ; Huntly BJP; Martincorena I; Anderson E et al.
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

Hematopoietic stem cells made BETter by inhibition.

Haematologica
2018-06 | Journal article
DOI: 10.3324/haematol.2018.193706
PMID: 29866885
PMC: PMC6058785
Contributors: Marando L; Huntly BJP
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs.

Nature genetics
2018-05 | Journal article
DOI: 10.1038/s41588-018-0114-z
PMID: 29736013
PMC: PMC6029661
Contributors: Gozdecka M; Meduri E; Mazan M; Tzelepis K; Dudek M; Knights AJ; Pardo M; Yu L; Choudhary JS; Metzakopian E et al.
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

Ezh2 and Runx1 Mutations Collaborate to Initiate Lympho-Myeloid Leukemia in Early Thymic Progenitors.

Cancer cell
2018-02 | Journal article
DOI: 10.1016/j.ccell.2018.01.006
PMID: 29438697
Contributors: Booth CAG; Barkas N; Neo WH; Boukarabila H; Soilleux EJ; Giotopoulos G; Farnoud N; Giustacchini A; Ashley N; Carrelha J et al.
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition.

Blood
2018-02 | Journal article
DOI: 10.1182/blood-2017-12-820035
PMID: 29463564
PMC: PMC6061932
Contributors: Gallipoli P; Giotopoulos G; Tzelepis K; Costa ASH; Vohra S; Medina-Perez P; Basheer F; Marando L; Di Lisio L; Dias JML et al.
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors.

Nature cell biology
2017-08 | Journal article
DOI: 10.1038/ncb3597
PMID: 28825697
PMC: PMC5633079
Contributors: Horton SJ; Giotopoulos G; Yun H; Vohra S; Sheppard O; Bashford-Rogers R; Rashid M; Clipson A; Chan WI; Sasca D et al.
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

Novel epigenetic therapies in hematological malignancies: Current status and beyond.

Seminars in cancer biology
2017-08 | Journal article
DOI: 10.1016/j.semcancer.2017.07.005
PMID: 28782607
Contributors: Gallipoli P; Huntly BJP
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients.

Leukemia
2017-07 | Journal article
DOI: 10.1038/leu.2017.210
PMID: 28674423
Contributors: Beck D; Thoms JAI; Palu C; Herold T; Shah A; Olivier J; Boelen L; Huang Y; Chacon D; Brown A et al.
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia.

Cell reports
2016-10 | Journal article
DOI: 10.1016/j.celrep.2016.09.079
PMID: 27760321
PMC: PMC5081405
Contributors: Tzelepis K; Koike-Yusa H; De Braekeleer E; Li Y; Metzakopian E; Dovey OM; Mupo A; Grinkevich V; Li M; Mazan M et al.
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation.

Leukemia
2016-10 | Journal article
DOI: 10.1038/leu.2016.280
PMID: 27740635
PMC: PMC5383931
Contributors: Kollmann K; Warsch W; Gonzalez-Arias C; Nice FL; Avezov E; Milburn J; Li J; Dimitropoulou D; Biddie S; Wang M et al.
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

Corrigendum: Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition.

Nature
2016-10 | Journal article
DOI: 10.1038/nature20144
PMID: 27760119
Contributors: Sciacovelli M; Gonçalves E; Johnson TI; Zecchini VR; da Costa AS; Gaude E; Drubbel AV; Theobald SJ; Abbo SR; Tran MG et al.
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition.

Nature
2016-08 | Journal article
DOI: 10.1038/nature19353
PMID: 27580029
PMC: PMC5136292
Contributors: Sciacovelli M; Gonçalves E; Johnson TI; Zecchini VR; da Costa AS; Gaude E; Drubbel AV; Theobald SJ; Abbo SR; Tran MG et al.
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

Independence of epigenetic and genetic diversity in AML.

Nature medicine
2016-07 | Journal article
DOI: 10.1038/nm.4136
PMID: 27387883
Contributors: Sasca D; Huntly BJ
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

Mll-AF4 Confers Enhanced Self-Renewal and Lymphoid Potential during a Restricted Window in Development.

Cell reports
2016-07 | Journal article
DOI: 10.1016/j.celrep.2016.06.046
PMID: 27396339
PMC: PMC4967476
Contributors: Barrett NA; Malouf C; Kapeni C; Bacon WA; Giotopoulos G; Jacobsen SEW; Huntly BJ; Ottersbach K
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

Functional interdependence of BRD4 and DOT1L in MLL leukemia.

Nature structural & molecular biology
2016-06 | Journal article
DOI: 10.1038/nsmb.3249
PMID: 27294782
Contributors: Gilan O; Lam EY; Becher I; Lugo D; Cannizzaro E; Joberty G; Ward A; Wiese M; Fong CY; Ftouni S et al.
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies.

Blood
2016-04 | Journal article
DOI: 10.1182/blood-2015-11-683334
PMID: 27121471
PMC: PMC4937362
Contributors: McKerrell T; Moreno T; Ponstingl H; Bolli N; Dias JM; Tischler G; Colonna V; Manasse B; Bench A; Bloxham D et al.
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance.

Blood
2015-12 | Journal article
DOI: 10.1182/blood-2015-07-604496
PMID: 26660431
PMC: PMC4705608
Contributors: Grimwade D; Ivey A; Huntly BJ
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central
grade
Preferred source (of 2)‎

BET inhibitor resistance emerges from leukaemia stem cells.

Nature
2015-09 | Journal article
DOI: 10.1038/nature14888
PMID: 26367796
PMC: PMC6069604
Contributors: Fong CY; Gilan O; Lam EY; Rubin AF; Ftouni S; Tyler D; Stanley K; Sinha D; Yeh P; Morison J et al.
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression.

The Journal of experimental medicine
2015-08 | Journal article
DOI: 10.1084/jem.20141661
PMID: 26304963
PMC: PMC4577832
Contributors: Giotopoulos G; van der Weyden L; Osaki H; Rust AG; Gallipoli P; Meduri E; Horton SJ; Chan WI; Foster D; Prinjha RK et al.
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

Somatic drivers of B-ALL in a model of ETV6-RUNX1; Pax5(+/-) leukemia.

BMC cancer
2015-08 | Journal article
DOI: 10.1186/s12885-015-1586-1
PMID: 26269126
PMC: PMC4542115
Contributors: van der Weyden L; Giotopoulos G; Wong K; Rust AG; Robles-Espinoza CD; Osaki H; Huntly BJ; Adams DJ
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

BET bromodomain inhibitors in leukemia.

Experimental hematology
2015-07 | Journal article
DOI: 10.1016/j.exphem.2015.06.004
PMID: 26163798
Contributors: Basheer F; Huntly BJ
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia.

Therapeutic advances in hematology
2015-06 | Journal article
DOI: 10.1177/2040620715577614
PMID: 26137202
PMC: PMC4480521
Contributors: Gallipoli P; Giotopoulos G; Huntly BJ
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia.

Oncogene
2015-04 | Journal article
DOI: 10.1038/onc.2015.92
PMID: 25893291
PMC: PMC4729186
Contributors: Giotopoulos G; Chan WI; Horton SJ; Ruau D; Gallipoli P; Fowler A; Crawley C; Papaemmanuil E; Campbell PJ; Göttgens B et al.
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors.

Stem cells (Dayton, Ohio)
2014-09 | Journal article
DOI: 10.1002/stem.1748
PMID: 24806995
PMC: PMC4282530
Contributors: Pellicano F; Scott MT; Helgason GV; Hopcroft LE; Allan EK; Aspinall-O'Dea M; Copland M; Pierce A; Huntly BJ; Whetton AD et al.
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.

Blood
2014-04 | Journal article
DOI: 10.1182/blood-2014-02-558114
PMID: 24764564
PMC: PMC4190617
Contributors: Placke T; Faber K; Nonami A; Putwain SL; Salih HR; Heidel FH; Krämer A; Root DE; Barbie DA; Krivtsov AV et al.
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

The New England journal of medicine
2013-12 | Journal article
DOI: 10.1056/NEJMoa1312542
PMID: 24325359
PMC: PMC3966280
Contributors: Nangalia J; Massie CE; Baxter EJ; Nice FL; Gundem G; Wedge DC; Avezov E; Li J; Kollmann K; Kent DG et al.
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia.

Leukemia
2013-11 | Journal article
DOI: 10.1038/leu.2013.338
PMID: 24220271
PMC: PMC3918873
Contributors: Dawson MA; Gudgin EJ; Horton SJ; Giotopoulos G; Meduri E; Robson S; Cannizzaro E; Osaki H; Wiese M; Putwain S et al.
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central

BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms.

Leukemia
2013-08 | Journal article
DOI: 10.1038/leu.2013.234
PMID: 23929215
Contributors: Wyspiańska BS; Bannister AJ; Barbieri I; Nangalia J; Godfrey A; Calero-Nieto FJ; Robson S; Rioja I; Li J; Wiese M et al.
Source: Self-asserted source
Huntly, BJP via Europe PubMed Central
Items per page:
Page 1 of 3

Peer review (12 reviews for 5 publications/grants)

Review activity for Cell reports medicine. (2)
Review activity for Cell stem cell. (4)
Review activity for Nature (2)
Review activity for Nature communications (3)
Review activity for Nature genetics. (1)
How many people are using ORCID?